Literature DB >> 11536215

Time-resolved X-ray scattering using synchrotron radiation applied to the study of a polymorphic transition in carbamazepine.

A D Edwards1, B Y Shekunov, R T Forbes, J G Grossmann, P York.   

Abstract

The thermodynamic status of alpha-carbamazepine has been clarified using equilibrium solubility measurements, differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), heated X-ray powder diffraction (XRPD), and temperature-controlled X-ray scattering techniques. alpha-Carbamazepine is the least stable of the three well-characterized anhydrous polymorphs of carbamazepine at 25 degrees C. In addition, it was confirmed that alpha-carbamazepine undergoes an exothermic transition to gamma-carbamazepine at 130 degrees C. The novel technique of time-resolved simultaneous small- and wide-angle X-ray scattering has been successfully applied to monitor this transition in situ. It was concluded that alpha-carbamazepine has a monotropic relationship with gamma-carbamazepine. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11536215     DOI: 10.1002/jps.1064

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  3 in total

1.  Solid-vapor interactions: influence of environmental conditions on the dehydration of carbamazepine dihydrate.

Authors:  Rahul Surana; Abira Pyne; Raj Suryanarayanan
Journal:  AAPS PharmSciTech       Date:  2004-12-31       Impact factor: 3.246

2.  Monitoring real time polymorphic transformation of sulfanilamide by diffuse reflectance visible spectroscopy.

Authors:  Tracy O Ehiwe; Bruce D Alexander; John C Mitchell; Martin J Snowden; Laura J Waters
Journal:  J Pharm Anal       Date:  2016-01-08

3.  Influence of Carbamazepine Dihydrate on the Preparation of Amorphous Solid Dispersions by Hot Melt Extrusion.

Authors:  Xiangyu Ma; Felix Müller; Siyuan Huang; Michael Lowinger; Xu Liu; Rebecca Schooler; Robert O Williams Iii
Journal:  Pharmaceutics       Date:  2020-04-20       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.